Regulation of Tissue Inflammation by Thrombin-Activatable Carboxypeptidase B (or TAFI)

  • Lawrence L.K. Leung
  • Toshihiko Nishimura
  • Timothy Myles
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 632)


Thrombin-activatable procarboxypeptidase B (proCPB or thrombin-activatable fibrinolysis inhibitor or TAFI) is a plasma procarboxypeptidase that is activated by the thrombin-thrombomodulin complex on the vascular endothelial surface. The activated CPB removes the newly exposed carboxyl terminal lysines in the partially digested fibrin clot, diminishes tissue plasminogen activator and plasminogen binding, and protects the clot from premature lysis. We have recently shown that CPB is catalytically more efficient than plasma CPN, the major plasma anaphylatoxin inhibitor, in inhibiting bradykinin, activated complement C3a, C5a, and thrombin-cleaved osteopontin in vitro. Using a thrombin mutant (E229K) that has minimal procoagulant properties but retains the ability to activate protein C and proCPB in vivo, we showed that infusion of E229K thrombin into wild type mice reduced bradykinin-induced hypotension but it had no effect in proCPB-deficient mice, indicating that the beneficial effect of E229K thrombin is mediated through its activation of proCPB and not protein C. Similarly proCPB-deficient mice displayed enhanced pulmonary inflammation in a C5a-induced alveolitis model and E229K thrombin ameliorated the magnitude of alveolitis in wild type but not proCPB-deficient mice. Thus, our in vitro and in vivo data support the thesis that thrombin-activatable CPB has broad anti-inflammatory properties. By specific cleavage of the carboxyl terminal arginines from C3a, C5a, bradykinin and thrombin-cleaved osteopontin, it inactivates these active inflammatory mediators. Along with the activation of protein C, the activation of proCPB by the endothelial thrombin-thrombomodulin complex represents a homeostatic feedback mechanism in regulating thrombin’s pro-inflammatory functions in vivo.


Abdominal Aortic Aneurysm Abdominal Aortic Aneurysm Fibrin Clot Clot Lysis Anticoagulant Property 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Bajzar, LNesheim, J., Morser, M(1996). TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271, 16603–16608PubMedCrossRefGoogle Scholar
  2. Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., et al. (2001). Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344, 699–709PubMedCrossRefGoogle Scholar
  3. Broze, G., Higuchi, D.A. (1996). Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 88, 3815–3823PubMedGoogle Scholar
  4. Campbell, W.D., Lazoura, E., Okada, N., Lazoura, H., (2002). Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 46, 131–134PubMedGoogle Scholar
  5. Coughlin, S.R. (2005). Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3, 1800–1814PubMedCrossRefGoogle Scholar
  6. Esmon, C.T. (2003). The protein C pathway. Chest 124, 26S–32SPubMedCrossRefGoogle Scholar
  7. Esmon, C.T. (2005). The interactions between inflammation and coagulation. Br J Haematol 131, 417–430PubMedCrossRefGoogle Scholar
  8. Gibbs, C.S., Coutre, S.E., Tsiang, M., Li, W.X., Jain, A.K., Dunn, K.E., Law, V.S., Mao, C.T., Matsumura, S.Y., Mejsa, S.J., Paborsky, L.R., Leung, L.L.K. (1995). Conversion of thrombin into an anticoagulant by protein engineering. Nature 378, 413–416PubMedCrossRefGoogle Scholar
  9. Leung, L.L.K., Gibbs, C.S. (1997). Modulation of thrombin’s procoagulant and anticoagulant properties. Thromb Haemost 78, 577–580PubMedGoogle Scholar
  10. Myles, T., Nishimura, T., Yun, T.HNagashima, M., Morser, JPatterson, A.J., Pearl, R.G., Leung, L.L.K. (2003). Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 278, 51059–51067PubMedCrossRefGoogle Scholar
  11. Nishimura, T., Myles, T., Piloponsky, P., Kao, P., Berry, G.J., Leung, L.L.K. (2007). Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood 109, 1992–1997PubMedCrossRefGoogle Scholar
  12. Redlitz, A., Tan, A.K., Eaton, D.L., Plow, E.F. (1995). Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 96, 2534–2538PubMedCrossRefGoogle Scholar
  13. Shinohara, T., Sakurada, C., Suzuki, T., Takeuchi, O., Campbell, W., Ikeda, S., Okada, N., Okasda, H., (1994). Pro-carboxypeptidase R cleaves bradykinin following activation. Int Arch Allergy Immunol 103, 400–404PubMedCrossRefGoogle Scholar
  14. Song, J., Nishimura, T., Garcia, M., Myles, T., Ho, P., Du, X.Y., Sharif, S., Leung, L., Robinson, W. (2007). Thrombin-activatable carboxypeptidase B prevents anti-collagen antibody induced arthritis. Clinical Immunology 123 Suppl, S98Google Scholar
  15. Tsiang, M., Paborsky, L.R., Li, W.X., Jain, A.K., Mao, C.T., Dunn, K.E., Lee, D.W., Matsumura, S.Y., Matteucci, M.D., Coutre, S.E., Leung, L.L.K., andGibbs, C.S. (1996). Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry 35, 16449–16457PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Lawrence L.K. Leung
    • 1
  • Toshihiko Nishimura
    • 1
  • Timothy Myles
    • 1
  1. 1.Department of Medicine, Division of Hematology, Stanford University School of Medicine and Veterans Administration Palo Alto Health Care SystemStanfordUSA

Personalised recommendations